A

Australian Alzheimer's Research Foundation | Clinical Trials Division

Research site

(Unclaimed)

Location

Suite 17, 95 Monash Avenue, Nedlands, Western Australia, Australia

Site insights

Top conditions

Top treatments

Gantenerumab

LY3314814

Aducanumab

Lanabecestat

Lecanemab

Semaglutide

221AD301

221AD302

Simufilam

JNJ-63733657

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 21 total trials

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration includ...

Enrolling

Alzheimer Disease

Mental Disorders

Drug: Placebo

Drug: Donanemab

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease (Reτain)

The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Comp...

Active, not recruiting

Preclinical Alzheimer's Disease

Drug: JNJ-64042056

Drug: Placebo

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease (Clarity AD)

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiorit...

Active, not recruiting

Early Alzheimer's Disease

Drug: Lecanemab SC

Drug: Placebo

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical...

Active, not recruiting

Preclinical Alzheimer's Disease

Early Preclinical Alzheimer's Disease

Drug: Lecanemab

Drug: Placebo